BDBM435144 US10584127, Compound E1-2.2::US11136328, Compound E1-2.2

SMILES Cc1ccc(COC(=O)N2CC[C@H](CNc3cncc4nncn34)C(F)(F)C2)cc1

InChI Key InChIKey=PNANHTBJHNWSGP-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 435144   

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM435144(US10584127, Compound E1-2.2 | US11136328, Compound...)
Affinity DataIC50: 10.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM435144(US10584127, Compound E1-2.2 | US11136328, Compound...)
Affinity DataIC50: 10.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM435144(US10584127, Compound E1-2.2 | US11136328, Compound...)
Affinity DataIC50: 10.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM435144(US10584127, Compound E1-2.2 | US11136328, Compound...)
Affinity DataIC50: 10.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM435144(US10584127, Compound E1-2.2 | US11136328, Compound...)
Affinity DataIC50: 1.00E+4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM435144(US10584127, Compound E1-2.2 | US11136328, Compound...)
Affinity DataIC50: 1.00E+7nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details
US Patent